Metabolism Disorder TRIZ Cases

Controlled-release octreotide polymers maintain steadier therapeutic levels for months, reducing hormone fluctuations and repeat injections.

The case uses CAD-PRS thresholds to target PCSK9 inhibitors, improving treatment efficacy and reducing wasted therapy.

This case uses high-affinity LEPR antibodies and fragments to down-regulate leptin signaling for cachexia and related disorders.

This case identifies active extract compounds and FAS mediation for suppressing weight gain and cholesterol synthesis under high-fat diets.

This case uses selective activated-carbon adsorption to reduce bitter components while maintaining α-glucosidase activity and recovery.

Gold clusters lower blood sugar. Ligands support insulin sensitivity in diabetes treatment.

Donor selection and pooling create consistent allogeneic MSC batches with reduced variability and immunogenicity for therapy.

Covalently linked α-galactosidase multimers sustain activity in plasma and lysosomal conditions for Fabry disease treatment.

Engineered PCSK9 antibodies inhibit PCSK9, helping restore LDL receptor expression when statins alone are insufficient.

Modified CDRs guide CB1 antibodies toward peripheral tissues, limiting blood-brain barrier penetration and CNS side effects.

This case addresses weak bacterial Cas9 activity in human cells using hairpin sgRNA and AAV delivery for in vivo editing.

This case identifies bacterial biomarkers and modulates gut populations for obesity diagnosis and treatment in cats and dogs.

For CKD and anticoagulant therapy, MK-7 and MKH2-7 restore Vitamin K-dependent carboxylation to help prevent tissue calcification.

This case selects early-harvested hop flowers by hue, then processes them into food products with antioxidant and anti-adipocyte action.

This case uses allithiamine, fursultiamine, and benfotiamine to reduce cortisol and ease hypercortisolism symptoms.

This case uses IL-4 peptide fragments as type I receptor agonists and type II antagonists for sustained weight control.

Targeted PGA mutations improve stability and activity, enabling over 90% conversion of protected insulin to free insulin.

This case shows how humanized beta klotho antibodies use defined CDRs to induce FGF19- and FGF21-like signaling for metabolic treatment.

Modified glucagon analogues with conjugated lysine side chains extend in vivo activity, reducing dosing frequency for NAFLD and NASH.

This case replaces peak plasma estimates with threshold times, intrinsic activity, and KD measurements for in vivo human bioequivalence.

A buffered sublingual GLP-1 formulation uses mucosal absorption for needle-free delivery with 2–10% bioavailability.

Compression molding, excipients, and staged forces help retain protein activity in solid masses for oral or targeted delivery.

KLK1 protein therapy addresses fetal growth restriction and preeclampsia while avoiding placental transfer and fetal harm.

Rotating drug combinations helps prevent desensitization during extended chronic-disease treatment.

This case uses oxyresveratrol derivatives in pharmaceutical compositions to inhibit adipocyte viability and promote fat reduction.

Albumin-binding CRF2 agonist peptides address urocortin's short half-life, enabling longer-lasting subcutaneous therapy.

This case uses propylene glycol, phosphate buffering, and pH 7.2–7.6 to limit degradation and polymerization in dual agonist liquids.

This case addresses unstable, hard-to-scale small-molecule water using atomization, ionization, and mixing to improve storage stability.

This case uses a codon-optimized α-galactosidase A gene and liver-specific promoters to reduce lifelong treatment and antibody risks.

This case uses antibodies to tune insulin-INSR signaling, improving glucose uptake while addressing injection and weight-gain drawbacks.

This case combines multi-receptor incretin activity with fatty acid conjugation for longer action and less dose-limiting GI effects.

This case shows rapid conversion of mature pancreatic exocrine cells into glucose-responsive insulin-producing cells without stem cells.

This case targets hypothalamic Clic1 to limit antipsychotic-related hyperphagia while preserving psychiatric treatment effects.

This case combines GIPR antagonism with GLP-1R agonism to address limited weight management and insulin regulation.

This composition uses Salvia and Paeonia extracts to lower triglycerides and cholesterol while suppressing fatty liver and visceral fat.

This case combines CD3/CD28 signals, co-stimulators, and cytokines to expand memory T cells, Tregs, and Th17 cells.

This case develops Formula I compounds that inhibit PCSK9, support oral administration, and lower LDL cholesterol.

Selective TRβ agonists target metabolic disease while limiting liver and cartilage damage.

DPP-4 inhibitor and metformin therapy supports glycemic control in CKD.

This ruminant nutrition case uses potassium phosphate boluses that dissolve in the rumen, reducing lung-entry risk during mineral treatment.

Controlled enzyme content, enteric coatings, and moisture-resistant packaging preserve activity for precise digestive dosing.

This case uses antigen-specific regulatory or cytotoxic T cells to suppress B cells while preserving beneficial immune responses.

This case combines benzodioxol GLP-1R agonists with ACC, DGAT2, KHK, or FXR agents to address NASH through complementary pathways.

This case integrates IL-10 and proinsulin genes into bacterial chromosomes for stable expression and oral T1D treatment.

Systematic R1–R6 structural changes yield compounds that reduce body weight and food consumption while simplifying dosing.

Balanced GIP, GLP-1, and glucagon activity extends efficacy while addressing gastrointestinal side effects and dosing frequency.

Click-reactive PEG hydrogel coatings protect living cells without impairing nutrient and oxygen diffusion or cell function.

Explore modified PYY analogs using amino acid substitutions and fatty acid linkers to extend half-life and support NPY2-selective therapy.

This case uses weekly pegzilarginase with a cobalt cofactor to lower plasma arginine and address difficult dietary management in ARG1-D.

This case uses mulberry extract to improve renal function while reducing oxidative stress, inflammation, and fibrosis in CKD.